Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Gelatin sales were strong in Japan and North America, while sales in India declined due to lower selling prices. Collagen peptides benefited from sales of customer products, demand for protein products and firm demand in the Indian and Asian markets. Food materials posted higher sales following a review of the product mix, while biomedical sales increased due to growth in overseas sales. Interim net income attributable to owners of the parent declined due in part to an impairment loss of ¥1,500 million in connection with the discontinuation of development of a new core system.
No matters to report
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥19,512 million (YoY +5.5%) |
| Operating profit | ¥2,388 million (YoY +2.8%) |
| Ordinary income | ¥2,546 million (YoY +6.6%) |
| Profit attributable to owners of the parent | ¥235 million (YoY -89.4%) |
| Net income per share | ¥12.91 |
| Equity ratio | End of the current fiscal period 55.3 / End of previous period 56.6 |
| Total assets | ¥44,457 million |
| Net assets | ¥30,281 million |
| Cash flows from operating activities | ¥2,215 million |
| Cash flows from investing activities | ¥-773 million |
| Cash flows from financing activities | ¥-43 million |
| Cash and cash equivalents at end of period | ¥5,060 million |
| Full-year earnings forecast | Net Sales ¥41,000 million (YoY +7.8%) / Operating profit ¥4,700 million (YoY +0.8%) / Ordinary income ¥4,800 million (YoY +0.3%) / Net income ¥1,400 million (YoY -57.4%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥41,000 million / Operating profit Not disclosed → ¥4,700 million / Ordinary income Not disclosed → ¥4,800 million / Net income Not disclosed → ¥1,400 million |
| Annual Dividend Forecast | ¥30 → ¥40 |
| Depreciation and amortization | ¥678 million |
| Impairment loss | ¥1,500 million |
| Breakdown of extraordinary income (loss) | Gain on sale of fixed assets ¥9 million, Gain on sale of investment securities ¥74 million, Loss on sale of non-current assets ¥0 million, Loss on disposal of fixed assets ¥4 million, Impairment loss ¥1,500 million |
| Disclosure regarding the going concern assumption | No matters to report |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 1 / Excluded company ニッタゼラチンホールディングInc. |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 18,373,974 Shares |
| Treasury Shares at Period-End | 145,288 Shares |
| Factors Behind Changes in Business Performance | Gelatin sales were strong in Japan and North America, while sales in India declined due to lower selling prices. Collagen peptides benefited from sales of customer products, demand for protein products and firm demand in the Indian and Asian markets. Food materials posted higher sales following a review of the product mix, while biomedical sales increased due to growth in overseas sales. Interim net income attributable to owners of the parent declined due in part to an impairment loss of ¥1,500 million in connection with the discontinuation of development of a new core system. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased in each of the gelatin, collagen peptides, food materials and biomedical product categories, reflecting strong sales, firm demand, growth in overseas sales and a review of the product mix. Meanwhile, interim net income attributable to owners of the parent declined due in part to an impairment loss of ¥1,500 million in connection with the discontinuation of development of a new core system.